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Edited by Irmgard SinningAbstract Photoaﬃnity crosslinking has been utilized to probe
the nature of the ligand–receptor interface for a number of G
protein-coupled receptor systems. Often the photoreactive benzo-
phenone moiety incorporated in the ligand is found to react with
a methionine in the receptor. We introduced methionines one-at-
a-time into the region 163–176 of the parathyroid hormone
receptor, and ﬁnd that crosslinking occurs to the side-chain of
methionine over a range of 11 amino acids. We call this the
‘‘Magnet Eﬀect’’ of methionine. Hence, crosslinking contact
points can be signiﬁcantly shifted by the presence of methionine
in a receptor domain.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Site-directed mutagenesis1. Introduction
The membrane-embedded nature of G protein-coupled
receptors (GPCRs) renders puriﬁcation and crystallization of
receptor a challenge. Thus far, rhodopsin is the only GPCR
for which a crystal structure is available. In the absence of
X-ray structural data, photoaﬃnity scanning (PAS) combined
with molecular modeling has proven to be a powerful
approach for obtaining insight into the nature of the ligand–
receptor three-dimensional complex. Such is the case for sev-
eral GPCRs and their peptide ligands, including receptors
for parathyroid hormone (PTH) [1], secretin [2], calcitonin
[3], cholecystokinin [4], neurokinin-1 [5], and angiotensin [6].
Photoaﬃnity crosslinking followed by digestive mapping iden-
tiﬁes interactions between a speciﬁc residue in the ligand and a
site within the receptor. For this purpose, a photoreactive
group is introduced into the peptide ligand at sites maintaining
native binding and activity. The current photoreactive group
of choice is p-benzoylphenylalanine (Bpa) due to increased eﬃ-
ciency in forming a covalent bond to the receptor and its con-
venience in handling [7]. The experimentally determinedAbbreviations: Bpa, p-benzoylphenylalanine; Bpan-PTH, [Bpan,
Nle8,18,Arg13,26,27,L-2-Nal23,Tyr34]bPTH(1–34)NH2; CNBr, cyanogen
bromide; Endo-F, endoglycosidase F/N-glycosidase F; N-ECD,
N-terminal extracellular domain; Nle, norleucine; PTH, parathyroid
hormone; PTHR1, PTH receptor-1
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doi:10.1016/j.febslet.2006.02.050contact sites – often a single residue on the receptor – are then
used in computer simulations, in the form of ligand–receptor
distance restraints, to develop models of the ligand–receptor
complex.
We employed PAS in a series of investigations to generate a
detailed experimentally derived model of the interaction of
PTH-(1–34) with its receptor, PTHR1. Based on our results,
the N-terminal extracellular domain (N-ECD) proximal to
the 7-helical bundle has emerged as critical for ligand-binding.
Incorporating photoreactive groups into the mid-region of
PTH-(1–34) (positions 11, 13, 15, and 21) all lead to interac-
tion with this region of PTH1R (residues 165–189) [8]. We
now present a ‘‘methionine scan’’ of receptor region [163–
176]. We ﬁnd that Bpa in position 11 of PTH reacts with
methionines placed throughout the entire receptor region
[169–176], and Bpa in position 21 of PTH reacts with methio-
nines throughout the entire receptor region [163–173]. The
ﬁndings presented here suggest a broadening of the resolution
of the model obtainable by PAS when methionine is in proxim-
ity to the intrinsic contact sites.2. Materials and methods
2.1. Materials
Peptide synthesis was carried out as described [1]. Cyanogen
bromide (CNBr) was from Aldrich (Milwaukee, WI), Na125I from
Amersham-Pharmacia (Arlington Heights, IL), and endoglycosidase
F/N-glycosidase F (Endo-F) from New England BioLabs (Beverly,
MA).
2.2. Cell culture
COS-7 cells were maintained in culture in Dulbecco’s Modiﬁed Ea-
gle Medium (Gibco) supplemented with 10% fetal bovine serum.
2.3. Receptor mutagenesis
Single-stranded phagemid DNA of PTH receptor-1 (PTHR1) was
prepared by infecting the PTHR1-transformed E. coli strain CJ236
with helper phage M13K07. The [T163M]-, [S168M]-, [E169M]-,
[V171M]-, [K172M]-, [F173M]-, [L174M]-, [T175M]-, [N176M]-, and
[V183M]PTHR1 site-directed mutants were constructed by oligonu-
cleotide mutagenesis of the single-stranded phagemid DNA. Clones
were selected and mutations conﬁrmed by DNA sequencing.
2.4. Transient transfection of COS-7 cells with mutant receptors
Six 15 cm-dishes with COS-7 cells were transfected by addition of
5.2 lg/dish DNA and 27 ll/dish FuGENE 6 Transfection Reagent
(Roche) in OPTI-MEM I Reduced Serum Medium (Gibco). The cells
were harvested after 18–24 h for photoaﬃnity-crosslinking.
2.5. Radioiodination and photoaﬃnity crosslinking
Radioiodination, photoaﬃnity crosslinking, and isolation of ligand–
receptor conjugates was carried out as described [1].blished by Elsevier B.V. All rights reserved.
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Fig. 2. Representative example of the photocrosslinking of 125I-Bpa21-
PTH to [K172M]PTHR1 with no competitor present (lane 1) or in the
presence of unlabeled native sequence ligand (lanes 2 and 3) or
unlabeled Bpa21-PTH (lanes 4 and 5). Similar results were obtained for
each PTHR1-mutant.
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Binding aﬃnities of the PTH analogs for mutant receptors were
determined using 125I-[Nle8,18,Tyr34]-bPTH-(1-34)NH2 as tracer [9].
2.7. PTH-stimulated adenylyl cyclase (luciferase) assay
Transfection of COS-7 cells with either wild-type or mutant receptor
was performed by adding 0.1 lg/well receptor DNA, 0.1 lg/well CRE-
luc, 0.1 lg/well Renilla-luc, and 1 ll/well FuGENE 6 to OPTI-MEM I.
The assay was carried out 18 h post-transfection using the Dual-Glo
Luciferase Assay System (Promega). Plates were read on a Mithras
LB940 multilabel plate reader (Berthold Technologies).
2.8. Enzymatic and chemical digestions
Digestions were carried out as described [8].
2.9. Molecular modeling
Extensive molecular dynamics simulations of the PTH(1–34)/
PTHR1 complex employed a water/decane/water simulation cell using
GROMACs programs following published methods [1,5]. During the
simulations, the ligand–receptor contact points were maintained by
distance restraints. A target distance of 14 A˚ between alpha carbons
of the Bpa residue in the ligand and each residue in the crosslinking site
in the receptor was used, allowing for extensive conformational free-
dom for the ligand to interact with receptor.3. Results
Single methionine mutations were introduced individually in
positions 163, 168, 169, 171–176, and 183 of the N-ECD of
PTHR1. Introduction of Met in position 170 was not at-
tempted since removal of the native Cys results in poor expres-
sion of mutant receptor [10]. The mutant receptors were
transiently expressed and assayed for binding and adenylyl cy-
clase activity. Binding aﬃnities were found to be in the range
of wild-type receptor (Fig. 1A). Adenylyl cyclase activities
were comparable to wild-type, and all receptors displayed a
full agonist response (Fig. 1B).
Two 125I-labeled PTH ligands containing Bpa in position 11
or 21 (Bpa11-PTH and Bpa21-PTH, respectively) were photo-
crosslinked to native and selected methionine-containing
mutant PTHR1s. Non-radiolabeled parent PTH-(1–34) or
Bpa-containing ligand competed against radiolabeled ligand
(see Fig. 2) for each of the receptor mutants, indicating a spe-
ciﬁc interaction of ligand with receptor. Crosslinked ligand–
receptor conjugates were isolated, partially puriﬁed, digested
with Endo-F and CNBr, and analyzed by SDS–PAGE. For na-
tive PTHR1 crosslinked to either Bpa11-PTH or Bpa21-PTH, a-12 -11 -10 -9 -8 -7 -6 -5
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Fig. 1. (A) Binding curves for several mutant PTH receptors in a competition
displayed by mutant receptors.19 kDa-band was observed after Endo-F and CNBr-treatment,
corresponding to receptor fragment [64–189] (cleavage at
Met63 and Met189, see lane 2, Fig. 3A and B).
Theoretically, four diﬀerent digestion schemes are possible,
depending on the site of reaction with respect to the Met
point mutation (deﬁned as MetX): if radical insertion occurs
N-terminal to MetX, receptor fragment Met64-MetX with a
molecular weight (MW) of 16–17 kDa is expected. If inser-
tion occurs C-terminal to MetX, receptor fragment
MetX-Met189 with MW = 5.7–6.6 kDa is expected. The in-
tact ligand is covalently bound to these fragments, contribut-
ing 4.3 kDa to the expected MW. If crosslinking occurs at the
methyl group of Met, CNBr hydrolysis will release a thiocy-
anomethyl derivative of the ligand with MW = 4.4 kDa [11].
If the c-position of methionine is labeled, no cleavage should
occur upon CNBr treatment and the receptor fragment [64–
189] (as wild-type) conjugated to intact ligand should be
obtained [12].
As shown inFig. 3, a lowMWband slightly above the 3.5 kDa
marker was obtained for every mutant tested between residues
169 and 176 when crosslinked to Bpa11-PTH, and for
[T163M]- up to mutant [F173M]PTHR1 when crosslinked to
Bpa21-PTH. This indicates that crosslinking occurs to the-12 -11 -10 -9 -8 -7 -6 -5
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binding assay. (B) PTH-stimulated adenylyl cyclase/luciferase activities
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Fig. 3. CNBr-digestion patterns of mutant PTH receptors. The characteristic low MW band indicating crosslinking to the methyl group of
methionine is marked by the arrow. Each conjugate was tested individually; fragments are adjusted with regard to MWmarkers, which are shown on
the left side of the gels. Lane 1: Native ligand–receptor conjugate. Lane 2: CNBr digestion of deglycosylated native ligand–receptor conjugate. Other
lanes: Non-digested and CNBr- and Endo-F-digested mutant ligand-receptor conjugates, as labeled below. (A) Crosslinking with Bpa21-PTH. (B)
Crosslinking with Bpa11-PTH.
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gions. This low MW band is predominant for samples
T163M_21, S168M_21, E169M_21, and V171M_11 (see
Fig. 3A and B), whereas samples V171M_21 and L174M_11
show a 19 kDa band similar to WT receptor in addition to
the low MW band, indicating crosslinking to both the methyl
group and the c-position of methionine. Other samples, such
as F173M_21 andE169M_11, give rise to several bands between
the 6.5 and the 14.3 kDa markers in addition to the low MW
band, suggesting crosslinking to a site in addition tomethionine.
Importantly, when methionine is incorporated outside the
receptor domain examined here (e.g., mutant [V183M]PTHR1),
the characteristic low MW band is not observed for either
Bpa11-PTH or Bpa21-PTH crosslinking. The mutant receptor
[N176M] shows the low MW weight band when crosslinked
to Bpa11-PTH, but not when crosslinked to Bpa21-PTH. Cross-
linking of Bpa21-PTH shows the low MW band up to mutant
[F173M]PTHR1, indicating that the ‘‘Met-reactive’’ range of
Bpa from position 21 in the ligand ceases at receptor position
174 or 175. Hence, the range of ‘‘Met-reactivity’’ can be demar-
cated.4. Discussion
For structural elucidation of a ligand–receptor complex by
photoaﬃnity labeling, the photoreactive moiety ideally should
react indiscriminately amongst the naturally occurring amino
acids. However, this is not the case. Deseke et al. have studied
diﬀerences in intrinsic reactivities of 10 natural amino acids to-
wards photoalkylation with benzophenone and found the
highest insertion rates for glycine, followed by methionine
[13]. Indeed, many studies report methionine as the contact site
for benzophenone crosslinking [1,3,11,14–18]. Macdonald
et al. reported that mutation of the primary contact site for
a substance P analog, Met174 in extracellular loop 2 of the
neurokinin-1 receptor, resulted in a switch to photoinsertion
a few residues away at Met181 [19]. If crosslinking occurs to
the e-methyl group of the methionine side-chain, the ligand–
receptor conjugate is cleaved at the methionine side-chain
upon CNBr-treatment, and release of thiocyanomethyl-deriva-
tized ligand occurs [11]. The characteristic low MW band cor-
responding to free ligand makes detection straightforward.
This observation was recently used by Escher and coworkers
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Fig. 4. Zoom into the model of the PTH ligand–receptor complex
showing the topological arrangement of the ligand (yellow) and
receptor (green). The ‘‘methionine-reactive’’ range of the receptor is
colored light green. Side-chains of receptor residues T163, F173, and
N176, are shown and labeled. Ligand positions 11 and 21 are
represented in ball-and-stick mode and labeled. Red: Oxygen. Blue:
Nitrogen.
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Scanning through three transmembrane domains of the angio-
tensin receptor, they identiﬁed the binding groove for Bpa in
position 8 of angiotensin [20].
Our study demonstrates that the preferential reactivity of
Bpa for methionine over other amino acids in a target domain
can be more pronounced than previously appreciated. Bpa re-
acts with methionine through a range of at least 8–11 amino
acids, spanning the regions 169–176 or 163–173 in the receptor,
from position 11 or 21 in the ligand, respectively. The region
163–173 of PTH1R extends over 16 A˚ in our model (see
Fig. 4). The methionine reactive regions of positions 11 and
21 of the ligand overlap, despite the Bpa residues being 10 res-
idues apart from each other in the ligand (in our model the
Ca–Ca distance between positions 11 and 21 is 13 A˚). We refer
to this phenomenon as the ‘‘Magnet Eﬀect’’ of methionine.
Our observations are in contrast to the 3.1 A˚ reactive radius
suggested for photoalkylation by benzophenone [7]. We postu-
late that highly reactive methionine captures states during the
process of ligand-binding which, based on our results, include
considerable conformational ﬂexibility or induced ﬁt.
The region 169–176 of PTHR1 was shown by NMR to adopt
an alpha-helical structure on the surface of the membrane [21].
Our recent results suggest that this helix might re-arrange and
fold back towards the helical bundle during ligand-binding
[8]. This conformational ﬂexibility might explain how methio-
nines on diﬀerent sides of the helix are captured by Bpa. Our
data does not indicate a pattern of increased methionine reac-
tivity from every third position of the receptor region, as would
be expected from a conformationally stable helix.
The implications of our observations extend beyond this
investigation of PTHR1. Many photoaﬃnity crosslinking re-
ports (including studies from us and others working on diﬀer-
ent ligand–receptor systems) which identiﬁed methionine as
the crosslinked residue [1,3,15,16], may now warrant interpre-tation in a new light. The identiﬁed sites of interaction might
have been signiﬁcantly shifted by the presence of methionine.
In general, the ‘‘Magnet Eﬀect’’ of methionine needs to be ta-
ken into consideration when reporting methionine as a site of
crosslinking or when using a methionine point mutation for
introduction of an additional CNBr cleavage site. The incorpo-
ration of the contact points from such studies into molecular
models of the ligand–receptor complex must be done with care,
since the precision of the identiﬁed points can be overesti-
mated. Rather, a limit should be applied to the resolution as-
cribed to a methionine contact point. A generally applied
distance of 14 A˚ for experimentally determined contact sites
(as observed in our eﬀorts to reﬁne the PTH-receptor model)
seems appropriate for such a limit.Acknowledgements: This work was supported by Grant DK-47940 (to
M.R.) and GM-54082 (to D.F.M.) from the National Institutes of
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